Scarica l'app Stockscreener
10.11
1.30%
0.13
Dopo l'orario di chiusura:
10.30
0.19
+1.88%
Precedente Chiudi:
$9.98
Aprire:
$9.98
Volume 24 ore:
922.69K
Relative Volume:
0.72
Capitalizzazione di mercato:
$666.96M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-6.3987
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
-10.61%
1M Prestazione:
-22.17%
6M Prestazione:
+28.79%
1 anno Prestazione:
+125.67%
Intervallo 1D:
$9.915
$10.47
Intervallo di 1 settimana:
$9.77
$11.53
Portata 52W:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta FULC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
10.11 | 658.38M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Can Fulcrum Therapeutics Inc. stock surprise with earnings upside2025 Volume Leaders & Stock Timing and Entry Methods - ulpravda.ru
Will Fulcrum Therapeutics Inc. stock outperform Dow Jones indexWeekly Profit Report & Long-Term Capital Growth Strategies - ulpravda.ru
How geopolitical tensions affect Fulcrum Therapeutics Inc. stock2025 Biggest Moves & Pattern Based Trade Signal System - ulpravda.ru
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterMarket Volume Summary & AI Forecast for Swing Trade Picks - ulpravda.ru
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionPrice Action & Community Trade Idea Sharing Platform - ulpravda.ru
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Currency Fluctuation Impact & Consistent Triple Returns - ulpravda.ru
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
2026 world cup results breakdown: Is Fulcrum Therapeutics Inc. stock supported by strong cash flows2026 world cup usa national team round of 32 playmakers pressing system odds analysis expert opinion - ulpravda.ru
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3%Time to Sell? - MarketBeat
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 3%Should You Buy? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fulcrum Therapeutics Earnings Notes - Trefis
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7%Should You Sell? - MarketBeat
RBC Capital maintains Fulcrum Therapeutics (FULC) sector perform recommendation - MSN
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study - Insider Monkey
Fulcrum Therapeutics (FULC) Price Target Increased by 32.56% to 19.38 - Nasdaq
How Fulcrum Therapeutics Inc. stock performs in stagflationWeekly Trade Summary & Low Volatility Stock Suggestions - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc stock is a must watch in 20252025 Investor Takeaways & High Yield Stock Recommendations - moha.gov.vn
FULC (Fulcrum Therapeutics) Price-to-Tangible-Book : 3.35 (As of Dec. 20, 2025) - GuruFocus
What makes Fulcrum Therapeutics Inc. stock attractive to growth fundsJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Why Fulcrum Therapeutics Inc. stock is considered a top pick2025 Retail Activity & Free Technical Pattern Based Buy Signals - Улправда
Is Fulcrum Therapeutics Inc. stock undervalued vs historical averages2025 Performance Recap & Community Driven Trade Alerts - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc. stock is a must watch in 2025 - Улправда
Published on: 2025-12-19 18:03:13 - DonanımHaber
Can Fulcrum Therapeutics Inc. stock deliver consistent earnings growthQuarterly Performance Summary & High Win Rate Trade Tips - DonanımHaber
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Market Trends: Will Fulcrum Therapeutics Inc. stock attract more institutional investorsWeekly Investment Report & Technical Entry and Exit Tips - Улправда
Insider Sell: Curtis Oltmans Sells Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
B of A Securities maintains Fulcrum Therapeutics (FULC) underperform recommendation - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% on Insider Selling - Defense World
Truist Financial Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - ca.investing.com
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com Nigeria
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
Owner RA Capital Management LP Sells 4,175,139 ($58.4M) Of Fulcrum Therapeutics Inc [FULC] - TradingView — Track All Markets
Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Expands Offering to $175M - GuruFocus
Fulcrum Therapeutics stock falls after pricing $175 million public offering By Investing.com - Investing.com Canada
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):